ChapterPDF Available

Continuous Positive Airway Pressure (CPAP)

Authors:
  • Mercy Nazareth Hospital Philadelphia PA
Continuous Positive Airway Pressure (CPAP)
Venessa L. Pinto; Sandeep Sharma.
Author Information
Last Update: February 12, 2018. Go to:
Introduction
Continuous positive airway pressure (CPAP) is a type of positive airway pressure, where
the air flow is introduced into the airways to maintain a continuous pressure to constantly
stent the airways open, in people who are breathing spontaneously. Positive end-
expiratory pressure (PEEP) is the pressure in the alveoli above atmospheric pressure at the
end of expiration. CPAP is a way of delivering PEEP but also maintains the set pressure
throughout the respiratory cycle, during both inspiration and expiration. It is measured in
centimeters of water pressure (cm H2O). CPAP differs from bilevel positive airway
pressure (BiPAP) where the pressure delivered differs based on whether the patient is
inhaling or exhaling. These pressures are known as inspiratory positive airway pressure
(IPAP) and expiratory positive airway pressure (EPAP). In CPAP no additional pressure
above the set level is provided, and patients are required to initiate all of their breaths.
The application of CPAP maintains PEEP, can decrease atelectasis, increases the surface
area of the alveolus, improves V/Q matching, and hence, improves oxygenation. It can also
indirectly aid in ventilation, although CPAP alone is often inadequate for supporting
ventilation, which requires additional pressure support during inspiration (IPAP on BiPAP)
for non-invasive ventilation.
Go to:
Anatomy
Patients inhale air is inhaled through the nose, and the air travels through the nasopharynx,
oropharynx, into the larynx, trachea, bronchi, bronchioles, and finally, to the alveoli.
Sometimes, portions of the respiratory tract can be occluded by excess tissue, tonsillar
overgrowth, the poor tone of the musculature, fatty excess, secretions among others. The
forced air delivered by CPAP helps to keep the airways patent and prevents collapse.
Go to:
Indications
Airway collapse can occur from various causes, and CPAP is used to maintain airway
patency in many of these instances. Airway collapse is typically seen in adults and children
who have breathing problems such as obstructive sleep apnea (OSA), which is a cessation
or pause in breathing while asleep. OSA may arise from a variety of causes such as obesity,
hypotonia, adenotonsillar hypertrophy, among others.
CPAP may be used in the neonatal intensive care unit (NICU) to treat preterm infants
whose lungs have not yet fully developed and who may have respiratory distress syndrome
from surfactant deficiency. Physicians may also use CPAP to treat hypoxia and decrease the
work of breathing in infants with acute infectious processes such as bronchiolitis and
pneumonia or for those with collapsible airways such as in tracheomalacia.
It is used in hypoxic respiratory failure associated with congestive heart failure in which it
augments the cardiac output and improves V/Q matching.
CPAP can aid oxygenation via PEEP prior to placement of an artificial airway during
endotracheal intubation.
It is used to successfully extubate patients that might still benefit from positive pressure
but who may not need invasive ventilation, such as obese patients with obstructive sleep
apnea (OSA) or patients with congestive heart failure.
Go to:
Contraindications
CPAP cannot be used in individuals who are not spontaneously breathing. Patients with
poor respiratory drive need invasive ventilation or non-invasive ventilation with CPAP plus
additional pressure support and a backup rate (BiPAP).
The following are relative contraindications for CPAP:
Uncooperative or extremely anxious patient
Reduced consciousness and inability to protect their airway
Unstable cardiorespiratory status or respiratory arrest
Trauma or burns involving the face
Facial, esophageal, or gastric surgery
Air leak syndrome (pneumothorax with bronchopleural fistula)
Copious respiratory secretions
Severe nausea with vomiting
Severe air trapping diseases with hypercarbia asthma or chronic obstructive
pulmonary disease (COPD)
Go to:
Equipment
CPAP therapy utilizes machines specifically designed to deliver a flow of constant pressure.
Some CPAP machines have other features as well, such as heated humidifiers. Components
of a CPAP machine include an interface for delivering CPAP.
CPAP can be administered in several ways based on the mask interface used:
Nasal CPAP: Nasal prongs that fit directly into the nostrils or a small mask that fits
over the nose
Nasopharyngeal (NP) CPAP: Administered via a nasopharyngeal tube- an airway
placed through the nose whose tip terminates in the nasopharynx. This has the
advantage of bypassing the nasal cavity, and CPAP is delivered more distally.
CPAP via face mask: A full face mask is placed over the nose and mouth with a good
seal. It can be used for those that are mouth breathers, or for pre-oxygenation in
spontaneously breathing patients prior to intubation.
A CPAP machine also includes straps to position the mask, a hose or tube that connects the
mask to the machine’s motor, a motor that blows air into the tube, and an air filter to purify
the air entering the nose.
Bubble CPAP is a mode of delivering CPAP used in neonates and infants where the pressure
in the circuit is maintained by immersing the distal end of the expiratory tubing in water.
The depth of the tubing in water determines the pressure (CPAP) generated. Blended and
humidified oxygen is delivered via nasal prongs or nasal masks and as the gas flows
through the system, it “bubbles” out the expiratory tubing into the water, giving a
characteristic sound. Pressures used are typically between 5 to 10 cm H2O. It requires
skilled nurses and respiratory therapists to maintain effective and safe use of the bubble
CPAP system.
For patients using CPAP in the outpatient setting at home, it is important to wear it
regularly while asleep overnight and during daytime naps. Some CPAP units also come with
a timed pressure “ramp” setting that starts the airflow at a low level and slowly raises the
pressure to the set level that may make it more comfortable and easier to which to become
accustomed.
Go to:
Preparation
In an out of hospital setting, at first CPAP patients should be monitored in a sleep lab where
the optimal pressure is often determined by a technologist manually titrating settings to
minimize apnea. A sleep doctor or pulmonologist can help find the most comfortable mask,
trial a humidifier chamber in the machine, or use a different CPAP machine that allows
multiple or auto-adjusting pressure settings. Auto-titrating CPAP machines use computer
algorithms and pressure transducer sensors to determine the ideal pressure to eliminate
apneic events.
Go to:
Complications
The first few nights on CPAP may be difficult, while patients acclimate. Many patients at
first find the mask uncomfortable, claustrophobic or embarrassing.
Side effects of CPAP treatment may include congestion, runny nose, dry mouth, or
nosebleeds; humidification can often help with these symptoms. Masks may cause
irritation or redness of the skin, and use of the right size mask and padding can minimize
pressure sores from tight contact with skin. The mask and tube must be kept clean,
regularly inspected and should be replaced every 3 to 6 months. Abdominal distension or a
sensation of bloating might occur which rarely can lead to nausea, vomiting and
subsequently aspiration this can be minimized by decreasing the pressure or gastric
decompression through a tube in hospitalized patients.
Compliance
In spite of several benefits of CPAP therapy, compliance remains a big problem both in the
inpatient and outpatient setting.
Physicians should monitor for compliance and follow up with their patients closely
especially during initiation of CPAP therapy to ensure long-term success. Patients must
disclose any adverse effects that may limit compliance which must then be addressed by
the physician. Patients also need long-term follow up with an annual office visit to check
equipment, titrate settings as needed, and to ensure ongoing mask and interface fit.
Continuing patient education on the importance of regular use and support groups help
patients obtain the maximum benefit of this therapy.
There may arise rare instances of respiratory distress where a hospitalized patient would
greatly benefit from CPAP but does not tolerate the mask or is not complaint due to
delirium, agitation or factors such as very young age in children or the elderly. In such
scenarios, mild sedation with low dose fentanyl or dexmedetomidine can be used to
improve compliance, until the therapy is no longer indicated. As the use of any sedative or
anxiolytic agent can lead to decrease in consciousness and decrease in respiratory drive
these patients should be monitored very closely. If adequate minute ventilation and or
oxygenation cannot be achieved, then management should include escalation to BiPAP or
intubation with mechanical ventilation following the code status and goals of care.
Go to:
Clinical Significance
It is a commonly used mode of PEEP delivery in the hospital setting. It is also commonly
used in the outpatient or home environment to treat sleep apnea. Benefits of starting CPAP
treatment include better sleep quality, reduction or elimination of snoring, and less
daytime sleepiness. People report better concentration and memory and improved
cognitive function. It can also improve pulmonary hypertension and lower blood pressure.
CPAP can be used safely safe for all ages, including children.
CPAP helps in achieving better V/Q matching and ensures maintenance of functional
residual capacity. CPAP is not associated with adverse effects of invasive mechanical
ventilation like excessive use of sedation and side effects of positive pressure ventilation
(volutrauma and barotrauma). In the inpatient setting, it should be monitored very closely
with vital signs, blood gases, and clinical profile. If there is any sign of deterioration
mechanical ventilation should be considered.
Go to:
Questions
To access free multiple choice questions on this topic, click here.
Go to:
References
1.
Brown LK, Javaheri S. Positive Airway Pressure Device Technology Past and Present:
What's in the "Black Box"? Sleep Med Clin. 2017 Dec;12(4):501-515. [PubMed]
2.
Schwab RJ, Badr SM, Epstein LJ, Gay PC, Gozal D, Kohler M, Lévy P, Malhotra A,
Phillips BA, Rosen IM, Strohl KP, Strollo PJ, Weaver EM, Weaver TE., ATS
Subcommittee on CPAP Adherence Tracking Systems. An official American Thoracic
Society statement: continuous positive airway pressure adherence tracking systems.
The optimal monitoring strategies and outcome measures in adults. Am. J. Respir.
Crit. Care Med. 2013 Sep 01;188(5):613-20. [PMC free article] [PubMed]
3.
Polin RA, Sahni R. Newer experience with CPAP. Semin Neonatol. 2002
Oct;7(5):379-89. [PubMed]
4.
Gupta S, Donn SM. Continuous positive airway pressure: Physiology and comparison
of devices. Semin Fetal Neonatal Med. 2016 Jun;21(3):204-11. [PubMed]
5.
Gupta S, Donn SM. Continuous Positive Airway Pressure: To Bubble or Not to
Bubble? Clin Perinatol. 2016 Dec;43(4):647-659. [PubMed]
6.
Casey JL, Newberry D, Jnah A. Early Bubble Continuous Positive Airway Pressure:
Investigating Interprofessional Best Practices for the NICU Team. Neonatal Netw.
2016;35(3):125-34. [PubMed]
7.
Tingting X, Danming Y, Xin C. Non-surgical treatment of obstructive sleep apnea
syndrome. Eur Arch Otorhinolaryngol. 2018 Feb;275(2):335-346. [PubMed]
8.
Brockbank JC. Update on pathophysiology and treatment of childhood obstructive
sleep apnea syndrome. Paediatr Respir Rev. 2017 Sep;24:21-23. [PubMed]
Copyright © 2018, StatPearls Publishing LLC.
This book is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any
medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative
Commons license, and any changes made are indicated.
Bookshelf ID: NBK482178PMID: 29489216
... CPAP is a type of non-invasive ventilation that provides continuous positive airway pressure, preserving airway openness and enhancing gas exchange. 6 This ventilation mode is commonly used in patients with acute respiratory failure, obstructive sleep apnoea and cardiogenic pulmonary oedema. When combined with pressure support ventilation (PSV), a ventilation method that supplements spontaneous breaths of the patient with pressure support, CPAP can be an effective strategy for managing pulmonary injury in patients who need respiratory support, but are not yet suitable candidates for invasive MV. 6 PCV is an invasive MV mode in which the pressure applied to the airway remains constant during inspiration, while the tidal volume varies depending on the patient's lung compliance and resistance. ...
... 6 This ventilation mode is commonly used in patients with acute respiratory failure, obstructive sleep apnoea and cardiogenic pulmonary oedema. When combined with pressure support ventilation (PSV), a ventilation method that supplements spontaneous breaths of the patient with pressure support, CPAP can be an effective strategy for managing pulmonary injury in patients who need respiratory support, but are not yet suitable candidates for invasive MV. 6 PCV is an invasive MV mode in which the pressure applied to the airway remains constant during inspiration, while the tidal volume varies depending on the patient's lung compliance and resistance. This approach can offer benefits to patients with pulmonary injuries, as it may decrease the risk of barotrauma, reduce the likelihood of volutrauma, and optimise patient-ventilator synchrony. ...
Article
Full-text available
Objective: To compare the efficacy of various ventilation approaches to the treatment of patient with patients with severe blunt chest trauma. Method: The retrospective study was conducted at the Cardiorespiratory Syndrome Ward of the First People's Hospital of Linping District, Hangzhou, China, and comprised data of patients with blunt pulmonary trauma admitted from December 2019 to February 2023. The patients were divided into three groups based on the ventilation support mode. Group 1 received synchronised intermittent mandatory ventilation + positive end-expiratory pressure, Group 2 received continuous positive airway pressure + pressure support ventilation, and Group 3 recieved pressure-controlled ventilation. Clinical curative effect, respiratory mode parameters, and blood gas analysis indicators of the groups were compared before and after the treatment. Data was analysd using SPSS 20. Results: Of the 227 patients, 71(31.3%) were in Group A; 62(87.3%) males and 9(12.7%) females with mean age 69.6±5.9 years. There were 74(32.6%) patients in Group 2; 59(79.7%) males and 15(20.3%) females with mean age 71.2±6.2 years. In Group 3, there were 82(36.1%) patients; 61(74.4%) males and 21(25.6%) females with mean age 69.0±6.0 years (p>0.05). Most patients 146(64.32%) recovered with no significant differences in treatment effect across the groups (p>0.05). Group 2 showed significant differences in respiratory parameters and blood gas indicators compared to the other groups (p<0.001). Conclusion: While all the three ventilation strategies had comparable treatment effect, continuous positive airway pressure + pressure support ventilation was associated with the most favourable respiratory parameters and blood gas analysis indicators. Key Words: Pulmonary injuries, Ventilation techniques, Comparative effectiveness, Blood gas analysis.
... "A significant decrease in BMI in patients using CPAP therapy compared to patients in the non-CPAP group was observed (p = 0.006), with a large effect size (η2 = 0.218). There was an average loss in BMI of 1.4 ± 3.5 kg/m2 in patients from the CPAP group, compared to an average gain of 1.6 ± 2.5 kg/m2 among the patients not using CPAP therapy" [12][13][14][15][16][17]. ...
... Additionally, modern CPAP devices often come with integrated humidifiers, which maintain airflow moisture levels, preventing airways' dryness and irritation. This feature is particularly beneficial for patients who experience nasal congestion or throat irritation, as it enhances comfort and supports consistent use [12]. Moreover, smart CPAP devices now include connectivity features that allow for remote monitoring. ...
Article
Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is a prevalent condition characterized by intermittent upper airway obstruction during sleep, leading to significant health issues, including cardiovascular disease, metabolic syndrome, and neurodegenerative disorders. The primary treatment for OSAHS is Continuous Positive Airway Pressure (CPAP) therapy, which maintains airway patency through a continuous flow of air, effectively reducing apnea-hypopnea indices, improving sleep quality, and lowering cardiovascular risks.
... Influence is implicated on adherence and overall therapeutic outcomes due to differences between nasal and full-face masks [23]. Furthermore, the pressure settings required to maintain airway patency are not uniform across individuals, making standardization difficult [24]. ...
Article
Full-text available
Background Obstructive sleep apnea (OSA) is a highly prevalent, yet under‐diagnosed sleep disorder and has a strong association with type 2 diabetes and diabetic retinopathy (DR). Vascular abnormalities, nocturnal glucose dysregulation, impaired blood flow, and hypoxia during OSA induce oxidative stress and promote the inflammatory pathways which increase the VEGF factor levels, leading to the progression of DR. Aims To date, continuous positive airway pressure (CPAP) is the most effective, gold‐standard treatment for patients with moderate to severe OSA. However, the implications of CPAP for the treatment of DR due to OSA is still a topic of ongoing debate. Conclusion Evidence suggests that the administration of CPAP therapy led to a reduction in retinal exudates and optical coherence tomography indices for retinal edema and also exhibited improvement in glycemic control, sleepiness, and overall health‐related quality of life. Nevertheless, there are limited studies present that have evaluated the impact of CPAP therapy on DR in patients with OSA and well‐designed studies are needed to confirm CPAP's therapeutic effect on DR despite these findings. Moreover, concerns regarding its long‐term safety, adherence challenges, and inconsistent study designs limit definitive conclusions about CPAP's efficacy in managing DR. This indicates the need for future studies to advocate for enhanced CPAP adherence strategies, refined diagnostic criteria for OSA, and large‐scale clinical trials to explore CPAP's therapeutic role in DR. Addressing these challenges could revolutionize clinical practices, optimize patient outcomes, and establish CPAP as a cornerstone in the integrated management of OSA and DR.
... These are also referred to as mandibular advancement splints or mandibular repositioning appliances. MAD has shown improvement in obstructive sleep apnoea patients, by reducing the systolic and diastolic blood pressure.11 CPAP is more effective than MAD for treating sleep apnoea in certain cases. ...
Article
Full-text available
Mandibular advancement device (MAD) has been described as an alternative treatment for obstructive sleep apnea patients. This is the case report showing the treatment of obstructive sleep apnea with a mandibular advancement device. Five months after fitting and titrating the MAD, the AHI (Apnoea and hypopnea index) was reduced from 80,.5 events/hour to 14.6 events/hr. and minimum oxyhemoglobin saturation (Spo2) increased from 46% to 83%
... This condition is typically managed with high-flow oxygen, standard pharmacological interventions, and urinary catheterization for diuresis monitoring (in accordance with the 2021 ESC guidelines for the diagnostics and treatment of acute and chronic heart failure) [3]; however, patients often deteriorate rapidly during prehospital transport, prompting the growing use of continuous positive airway pressure (CPAP) therapy in the field [4]. CPAP is administered to conscious patients who are capable of cooperating and are spontaneously breathing through a noninvasive facemask, with a positive airway pressure applied throughout the entire respiratory cycle [5,6]. CPAP provides several advantages for patients with pulmonary edema, particularly acute cardiogenic pulmonary edema. ...
Article
Full-text available
Background: CPAP has been shown to be particularly beneficial in the management of acute cardiogenic pulmonary edema by reducing both preload and afterload, thus decreasing the work of breathing and improving oxygenation. Methods: This study was a prospective observational study, conducted in the period from 2022 to 2024, assessing the effectiveness and safety of prehospital CPAP therapy use in patients with acute cardiogenic pulmonary edema, administered alongside standard care. Results: In this study, 50 patients with acute cardiogenic pulmonary edema were treated by physician-led emergency teams in the Canton of Sarajevo. CPAP significantly improved clinical parameters across all time points. Systolic blood pressure decreased from 151.0 ± 41.0 mmHg at initial contact to 138.4 ± 32.0 mmHg before transportation and further to 130.2 ± 28.5 mmHg upon hospital admission (p < 0.001). Diastolic pressure dropped from 85.6 ± 17.2 mmHg to 81.1 ± 15.2 mmHg before transportation (p = 0.018), with a slight further decrease to 80.2 ± 13.9 mmHg (p = 0.083). Heart rate fell from 114 ± 26.4 bpm to 111.3 ± 24.9 bpm before transportation (p = 0.003) and finally to 99.5 ± 18.2 bpm before hospital admission (p < 0.001). Respiratory rate decreased from 31.0 ± 10.2 to 28.0 ± 10.5 breaths/min (p = 0.002) and further to 22.6 ± 7.3 breaths/min (p < 0.001). End-tidal CO2 levels increased from 28.0 mmHg (23.5; 33.5) to 30.0 mmHg before transportation (p < 0.001), and to 35.0 mmHg (32.0; 37.5) before hospital admission (p < 0.001). Oxygen saturation improved from 79.0% (72.0; 81.0) to 84.0% before transportation (p < 0.001) and reached 94.0% (91.0; 98.2) before hospital admission (p < 0.001). VAS scores for dyspnea significantly dropped from 8.0 (6.0; 8.2) at initial contact to 6.0 (4.0; 8.0) before transportation (p < 0.001) and further to 4.0 (3.0; 5.0) before hospital admission (p < 0.001), indicating substantial symptom relief. ECG findings remained stable throughout the intervention. Conclusions: Prehospital CPAP therapy significantly improved clinical outcomes in cardiogenic pulmonary edema, including reductions in blood pressure, heart rate, respiratory rate, and enhanced oxygenation and symptom relief. These findings support its broader use in emergency care, even during short transport times.
... • Positive airway pressure (PAP) therapy: Continuous PAP (CPAP) or adaptive servoventilation (ASV) devices help maintain airway patency and reduce apneas during sleep (Pinto & Sharma, 2023). ...
Article
Full-text available
This review explores how organic solvents, pesticides, and heavy metals, as prevalent environmental toxins, impact human health, particularly the nervous system, and their association with central sleep apnea (CSA). These toxins disrupt neural function through various mechanisms, including direct neurotoxic effects, neurotransmission interference, oxidative stress induction, and inflammatory responses. Organic solvents, prevalent in industrial and household products, compromise neuronal membrane integrity, disrupt neurotransmitter balance, and induce oxidative stress. These effects impair neuronal signaling critical for regulating breathing during sleep, contributing to CSA development. Pesticides inhibit enzymes involved in neurotransmitter production and disrupt neurotransmitter receptor function, leading to imbalances that affect respiratory control. Oxidative stress induced by pesticides further exacerbates neuronal damage, impairing the brainstem’s ability to maintain regular breathing patterns. Heavy metals interfere with neuronal ion channels, induce oxidative stress, and trigger inflammatory responses in the nervous system. These disruptions impair neuronal function in the brainstem responsible for respiratory regulation, resulting in apnea episodes during sleep. The diagnosis of toxin-induced CSA involves comprehensive evaluations, including exposure history, physical examinations, neuroimaging, laboratory tests, polysomnography, and neurophysiological testing. Differential diagnosis excludes other potential causes, ensuring accurate identification of toxin-induced CSA. Treatment strategies focus on eliminating toxin exposure, pharmacological interventions to manage symptoms, adjunctive therapies, and nutritional support. Managing toxin-induced CSA requires a multidisciplinary approach involving pulmonologists, neurologists, and toxicologists, among others, to optimize patient outcomes through targeted interventions and ongoing monitoring. Education and counseling promote patient engagement by fostering a comprehensive understanding and effective management of the condition—enhancing overall respiratory health and patient quality of life (QoL).
... Continuous positive airway pressure (CPAP) reduces pulmonary atelectasis associated with anaesthesia, helps maintain functional residual capacity, improves V/Q matching and oxygenation, and avoids airway collapse associated with obstructive apnoea [11]. However, performing pulmonary RFA with positive airway pressure may increase the frequency or severity of RFA complications. ...
Article
Full-text available
Objective To evaluate the safety of a minimum continuous positive airway pressure of 4 cmH 2 O (CPAP + 4) during computed tomography (CT)-guided radiofrequency ablation (RFA) for lung malignancies under procedural sedation and analgesia (PSA). Methods This was a prospective, randomised, single-blind, parallel-group, placebo-controlled trial with an open-label medical device conducted at a single tertiary university hospital in Barcelona, Spain. Forty-six patients over 18 years of age scheduled for CT-guided RFA of a malignant pulmonary tumour under PSA were randomised to receive either CPAP + 4 or a modified mask for placebo CPAP (Sham-CPAP). Exclusion criteria included contraindications for RFA, refusal to participate, inability to understand the procedure or tolerate the CPAP test, lung biopsy just prior to RFA, intercurrent diseases, or previous randomisation for additional pulmonary RFA. Primary outcomes were the percentage of patients reporting at least one serious adverse event (SAE), classification for complications from the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and Clavien-Dindo classifications for complications, hospital stay, and readmissions. Secondary outcomes included adverse events (AEs), respiratory parameters, airway management, and the local radiological efficacy of pulmonary ablation. Results CPAP + 4 prolonged hospital stay (1.5 ± 1.1 vs. 1.0 ± 0 inpatient nights, p = 0.022) and increased the risk of AE post-RFA (odds ratio (95% CI): 4.250 (1.234 to 14.637), p = 0.021 with more pneumothorax cases ( n = 5/22, 22.7% vs. n = 0/24, 0%, p = 0.019). Per-protocol analysis revealed more SAEs and CIRSE grade 3 complications in the CPAP + 4 group (23.5% vs. 0%, p = 0.036). No significant differences were found in the effectiveness of oxygenation, ventilation, or pulmonary ablation. Conclusion CPAP is unsafe during CT-guided RFA for lung cancer under PSA even at the lowest pressure setting. Trial registration ClinicalTrials.Gov, ClinicalTrials.gov ID NCT02117908, Registered 11 April 2014, https://www.clinicaltrials.gov/study/NCT02117908 Critical relevance statement This study highlights the hazards of continuous positive airway pressure during radiofrequency ablation of lung cancer, even at minimal pressures, deeming it unsafe under procedural sedation and analgesia in pulmonary interventional procedures. Findings provide crucial insights to prioritise patient safety. Key Points No prior randomised controlled trials on CPAP safety in percutaneous lung thermo-ablation. Standardised outcome measures are crucial for radiology research. CPAP during lung RFA raises hospital stay and the risk of complications. CPAP is unsafe during CT-guided RFA of lung cancer under procedural sedoanalgesia. Graphical Abstract
Article
Full-text available
Background Obstructive sleep apnoea increases risk of respiratory depression with administration of sedatives, narcotics or anxiolytics. To reduce adverse events during hospital admission, we implemented STOP-BANG screening to prompt respiratory monitoring for inpatients receiving these medications. This study reports on protocol development, implementation and an initial analysis over 5 years to evaluate implementation success and outcomes. Intervention The STOP-BANG measure was embedded in the nurse navigator at admission. If the score was ≥3 and sedatives, narcotics and/or anxiolytics were ordered, the provider was prompted to monitor patients with continuous pulse oximetry and/or capnography. Methods We assessed the impact of the intervention using a retrospective pre–post design. Preprotocol data from all adult inpatients over a 2.5-year period, and postprotocol data from all adult inpatients from over a 5-year period, were extracted from the electronic health record. Outcomes included use of monitoring; adverse events during hospitalisation were included to evaluate the effects of the intervention: mortality, rate of rapid response team events, reversal and/or rescue, intensive care unit admission and orders for positive airway pressure equipment. Results The combined preprotocol and postprotocol sample included 254 121 patients. After protocol implementation, overall mortality for patients receiving sedatives, narcotics or anxiolytics decreased slightly from 2.1% to 1.9% (p<0.001). In the postprotocol cohort only (n=193 744), monitored patients had a higher probability of experiencing all adverse events. Among monitored patients, mortality was lowest in the high-risk group (STOP-BANG≥5). Discussion Triaging by STOP-BANG coupled with monitoring appeared to be helpful for patients at highest risk of obstructive sleep apnoea. Given the complexity of obstructive sleep apnoea, further pursuit of subphenotypes is warranted.
Article
Full-text available
Introduction Sleep disorders represent common complaints in different medical illnesses. They encompass a risk for diverse inflammatory, metabolic, and cardiovascular diseases. Sleep disorders include disorders of hypersomnolence, insomnia, parasomnias, sleep-related movement disorders, circadian rhythm sleep-wake-disorders, and sleep-related breathing disorders, each one of which was associated with increased cardiovascular disease risk in a different mechanism. In this review, we address the most recent research on the correlation between sleep and CVD. Methods The literature on sleep disorders and their potential links to various cardiovascular diseases was reviewed in narrative form. For the published papers up to June 2023, we searched the databases of PubMed and Google Scholar. Literature demonstrating the relationship between these illnesses, pathophysiological mechanisms, diagnosis, and various therapeutic approaches was included. Results Sleep disorders were significantly linked to heart rate variability, hypertension, and obesity, which can eventually result in cardiovascular consequences and affect mortality and morbidity. The disruption in sleep cycles, which can be noticed in different sleep disorders, can obviously result in blood pressure, heart rate, and other cardiac functions. The clinical assessment acts as the cornerstone in the diagnosis of different spectrums of sleep disorders. The management of sleep disorders ranges from cognitive-behavioral therapy to continuous positive airway pressure (CPAP). Conclusion Additional research on the topic is needed to pinpoint any potential links and pathological processes. To improve clinical treatment and preventive measures, further observational studies should emphasize the reliability of early diagnostic signs.
Article
Full-text available
Obstructive sleep apnea syndrome (OSAS), a pervasive disease, is closely associated with complications such as cardiovascular diseases, neurocognitive diseases, and metabolic syndromes. Continuous positive airway pressure (CPAP) is the standard treatment for OSAS, with low compliance due to multifarious factors. The two other modes of ventilation, bi-level positive airway pressure (BPAP) and autotitrating positive airway pressure (APAP), which were developed from CPAP, are slightly different from CPAP in specific groups, as well as the corresponding treatment effect and compliance. The compliance of traditional positional therapy is not high, but with the emergence of the neck-based position treatment device, its compliance and indications have changed. Although CPAP is superior to mandibular advancement device (MAD) in improving AHI, MAD seems to be comparable to CPAP in improving other indicators. Corticosteroids and leukotriene receptor antagonists are effective treatments for mild OSAS children. Whether corticosteroids can be used in other OSAS groups and their adjunctive functions to CPAP remains unclear. The combination of these two kinds of drugs appears to be more effective than single drug. Researches on transcutaneous electrical stimulation are still not enough. Its effectiveness and stimulation settings still need further study. This review summarized the various OSAS non-surgical treatments from indications, treatment outcomes, compliance, adverse reactions, and recent progress.
Article
Full-text available
BACKGROUND: Continuous positive airway pressure (CPAP) is considered the treatment of choice for obstructive sleep apnea (OSA), and studies have shown that there is a correlation between patient adherence and treatment outcomes. Newer CPAP machines can track adherence, hours of use, mask leak, and residual apnea-hypopnea index (AHI). Such data provide a strong platform to examine OSA outcomes in a chronic disease management model. However, there are no standards for capturing CPAP adherence data, scoring flow signals, or measuring mask leak, or for how clinicians should use these data. METHODS: American Thoracic Society (ATS) committee members were invited, based on their expertise in OSA and CPAP monitoring. Their conclusions were based on both empirical evidence identified by a comprehensive literature review and clinical experience. RESULTS: CPAP usage can be reliably determined from CPAP tracking systems, but the residual events (apnea/hypopnea) and leak data are not as easy to interpret as CPAP usage and the definitions of these parameters differ among CPAP manufacturers. Nonetheless, ends of the spectrum (very high or low values for residual events or mask leak) appear to be clinically meaningful. CONCLUSIONS: Providers need to understand how to interpret CPAP adherence tracking data. CPAP tracking systems are able to reliably track CPAP adherence. Nomenclature on the CPAP adherence tracking reports needs to be standardized between manufacturers and AHIFlow should be used to describe residual events. Studies should be performed examining the usefulness of the CPAP tracking systems and how these systems affect OSA outcomes.
Article
Since the introduction of continuous positive airway pressure (PAP) for the treatment of obstructive sleep apnea (OSA) in 1981, PAP technology has diversified exponentially. Compact and quiet fixed continuous PAP flow generators, autotitrating PAP devices, and bilevel PAP devices that can treat multiple sleep-disordered breathing phenotypes including OSA, central sleep apnea (CSA), combinations of OSA and CSA, and hypoventilation are available. Adaptive servo-ventilators can suppress Hunter-Cheyne-Stokes breathing and CSA and treat coexisting obstructive events. Volume-assured pressure support PAP apparatus purports to provide a targeted degree of ventilatory assistance while also treating cooccurring OSA and/or CSA.
Article
Obstructive sleep apnea syndrome (OSAS) is common in childhood and is characterized by recurrent upper airway obstructive events during sleep that produce significant neurocognitive and cardiovascular sequelae. The pathophysiology of childhood OSAS is complex and involves mechanical airway obstruction often secondary to adenotonsillar hypertrophy. However, neuromotor abnormalities and instability of central ventilatory control are also implicated. Several surgical and non-surgical treatment options for childhood OSAS are available, and will be discussed. Some of these include adenotonsillectomy, lingual tonsillectomy, supraglottoplasty, continuous positive airway pressure (CPAP), rapid maxillary expansion, oral appliance therapy, anti-inflammatory treatments, and supplemental oxygen.
Article
Continuous positive airway pressure (CPAP) systems can be broadly grouped into continuous flow or variable flow devices. Bubble CPAP (bCPAP) is a continuous flow device and has physiologic properties that could facilitate gas exchange. Its efficacy has been reported to be similar to variable flow CPAP systems when used as a primary mode of respiratory support. Post-extubation bCPAP is reported to significantly reduce extubation failure rates among preterm infants ventilated for less than 2 week when compared to Infant flow driver CPAP (variable flow). bCPAP has been successfully used in resource-poor settings. The success on CPAP is however dependant on good nursing care and clear management protocols for weaning and escalation of care.
Article
A BSTRACT Premature neonates delivered <32 completed weeks gestation are unprepared to handle the physiologic demands of extrauterine life. Within the respiratory system, alveolar instability and collapse can cause decreased functional residual capacity, impaired oxygenation, and hypoxemia leading to respiratory distress syndrome. Supportive measures are indicated immediately after birth to establish physiologic stability including bubble continuous positive airway pressure (CPAP) or endotracheal intubation and mechanical ventilation. CPAP is a noninvasive, gentle mode of ventilation that can mitigate the effects of lung immaturity, but prolonged use can increase the risk for nasal breakdown. Strategies to mitigate this risk must be infused as best practices in the NICU environment. The purpose of this article is to propose an evidence-based best practice care bundle for the early initiation of CPAP in the delivery room and associated skin barrier protection strategies for premature neonates <32 weeks gestation and weighing <1,500 g.
Article
Nasal continuous positive airway pressure (CPAP) is increasingly used for respiratory support in preterm babies at birth and after extubation from mechanical ventilation. Various CPAP devices are available for use that can be broadly grouped into continuous flow and variable flow. There are potential physiologic differences between these CPAP systems and the choice of a CPAP device is too often guided by individual expertise and experience rather than by evidence. When interpreting the evidence clinicians should take into account the pressure generation sources, nasal interface, and the factors affecting the delivery of pressure, such as mouth position and respiratory drive. With increasing use of these devices, better monitoring techniques are required to assess the efficacy and early recognition of babies who are failing and in need of escalated support.
Article
Progress in neonatal intensive care is closely linked to improvements in the management of respiratory failure in small infants. Current modalities of ventilatory assistance range from more benign continuous positive airway pressure (CPAP) to various modes of mechanical ventilation (including high frequency ventilation). The advent of less invasive methods of delivering CPAP has permitted earlier treatment of infants with respiratory distress syndrome and avoided the need for mechanical ventilation. Children's Hospital of New York (Columbia University) places all spontaneously breathing infants on nasal prong CPAP as the first mode of respiratory support. The early initiation of nasal prong CPAP in combination with a tolerance to elevated PCO(2) levels has reduced the incidence of chronic lung disease to <5% in infants weighing less than 1500g. This report will present an historical review and summarize the experience with CPAP at Columbia and other centres. In addition, it reviews the clinical applications and physiological effects of CPAP in preterm infants with respiratory distress syndrome.
), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated
This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated. Bookshelf ID: NBK482178PMID: 29489216